American Renal Associates Holdings Inc (NYSE:ARA) – Stock analysts at Leerink Swann issued their Q1 2018 EPS estimates for American Renal Associates in a research report issued on Thursday. Leerink Swann analyst A. Gupte forecasts that the company will post earnings per share of $0.13 for the quarter. Leerink Swann currently has a “Market Perform” rating and a $27.00 target price on the stock. Leerink Swann also issued estimates for American Renal Associates’ FY2018 earnings at $0.86 EPS, FY2019 earnings at $0.95 EPS and FY2020 earnings at $1.14 EPS.
American Renal Associates (NYSE:ARA) last released its quarterly earnings data on Tuesday, March 6th. The company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.03. The firm had revenue of $194.40 million for the quarter, compared to analyst estimates of $195.15 million. American Renal Associates had a negative net margin of 1.00% and a positive return on equity of 14.51%. American Renal Associates’s quarterly revenue was down 2.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.26 earnings per share.
Shares of American Renal Associates (ARA) opened at $22.33 on Friday. The firm has a market cap of $701.57 and a PE ratio of -72.03. American Renal Associates has a 12 month low of $9.91 and a 12 month high of $24.07. The company has a debt-to-equity ratio of 4.28, a quick ratio of 1.13 and a current ratio of 1.20.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. We Are One Seven LLC acquired a new stake in American Renal Associates during the fourth quarter worth about $131,000. The Manufacturers Life Insurance Company increased its stake in shares of American Renal Associates by 19.7% in the second quarter. The Manufacturers Life Insurance Company now owns 8,778 shares of the company’s stock valued at $162,000 after purchasing an additional 1,443 shares during the period. Dimensional Fund Advisors LP acquired a new stake in shares of American Renal Associates in the second quarter valued at approximately $230,000. Citadel Advisors LLC acquired a new stake in shares of American Renal Associates in the third quarter valued at approximately $200,000. Finally, Alliancebernstein L.P. increased its stake in shares of American Renal Associates by 3.0% in the second quarter. Alliancebernstein L.P. now owns 13,900 shares of the company’s stock valued at $258,000 after purchasing an additional 400 shares during the period. Hedge funds and other institutional investors own 91.64% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3252386/american-renal-associates-holdings-inc-to-post-q1-2018-earnings-of-0-13-per-share-leerink-swann-forecasts-ara.html.
American Renal Associates Company Profile
American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.
Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.